CommercialCoverageMedium impact

23-279sum Medication Trend Updates and Formulary Changes- 2nd Quarter 2023

Q: Who is affected by this change?

This affects Health Net Rheumatology, Gastroenterology, Family Medicine, Internal Medicine, Pain Management, Psychiatry providers in CA on Commercial, Medicaid, Medicare Advantage plans.

Health Net·CA · Rheumatology, Gastroenterology, Family Medicine +3 more·Pharmacy

Effective date

Not stated

We identified it

Jun 20, 2026

Days to comply

—

Summary

Health Net updated their Q2 2023 formulary with new Humira biosimilars becoming available and simplified buprenorphine prescribing requirements (no longer needs X-Waiver). Formulary changes affect commercial, Medi-Cal, and Medicare Part D coverage with specific alternatives and restrictions listed in the complete update document.

Action Required

Action needed

Immediately: Review the complete Health Net provider update 23-279 PDF in the Provider Library to identify specific formulary changes affecting your patients. Update prescribing protocols to reflect new Humira biosimilar options and simplified buprenorphine prescribing (standard DEA number only). Contact appropriate Health Net pharmacy help lines for coverage verification when prescribing affected medications.

Related policy hubs

Health Net policies CA policy changes Rheumatology Gastroenterology Family Medicine Internal Medicine Pain Management Psychiatry